Skip to content

HELIX DIAGNOSTICS

Pharmacogenomics (PGx) Level A Panel

Test Description

This test evaluates a patient’s metabolizer status for 15 genes, which can aid in appropriate medication selection and dosing to reduce risk of side effects and treatment failure for cancer, cardiovascular disease, pain, mental health and other conditions. Recommendations and interpretation for dosage and prescription are based on guidelines set forth by CPIC and meet Level A priority for this test. Variant classifications are based on the combination of alleles found in the given individual and data set forth by CPIC. Note: This test has not been reviewed, approved, or endorsed by CPIC.

Genes Tested (15)

ABCG2
CYP2D6
CYP2C19
CYP2C9
CYP3A5
CYP4F2
DPYD
HLA-B
IFNL3
IFNL4
MT-RNR1
NUDT15
SLCO1B1
TPMT
VKORC1

Important Test Information

Turnaround time: Typically 7-10 days (standard), Typically < 5 minutes (requery)

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.

Other Tests to Consider

Malignant Hyperthermia Susceptibility Panel

3 genes

Pharmacogenomics (PGx) APOE Test

Pharmacogenomics (PGx) Fluoropyrimidines DPYD Test

Pharmacogenomics (PGx) Pain Panel

6 genes